Vast Therapeutics to Present Phase 1 Data on Nitric Oxide Therapy ALX1 at ATS 2026
Vast Therapeutics, a clinical-stage life science company, is set to present its Phase 1 study data on ALX1, an inhaled drug candidate, at the American Thoracic Society (ATS) 2026 International Conference. The conference will be held in Orlando, Florida, from May 15-20. ALX1 is a first-in-class, small molecule nitric oxide prodrug designed to offer dual-action anti-inflammatory and anti-microbial benefits without the toxicities associated with dosage. The presentation will focus on the safety, tolerability, and pharmacokinetics of ALX1, highlighting its novel approach for targeted delivery of nitric oxide to the lungs. The session, titled 'The Latest in Airway Symptoms and Disease,' will feature a poster presentation by Dr. Paul Bruinenberg, Chief Medical Officer of Vast Therapeutics. 
